Assess whether the primary endpoint will survive FDA scrutiny after a DSMB

SITUATION 505(b)(2) development lead in a mid-size sponsor after a complete response letter has one working extract — disproportionate reporting signal workbook — after a DSMB note on an imbalance that is not yet a signal. If disproportionate reporting signal workbook cannot support the primary endpoint will, the only defensible Pharma & Life Sciences output is hold.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in disproportionate reporting signal workbook — reopen intake, do not close the primary endpoint will. 4. Two facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal conflict for 505(b)(2) development lead; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim 505(b)(2) development lead would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.